FDA's GLP-1 Compounding Crackdown: What It Means for Telehealth Staffing and Compliance

The FDA sent 30 warning letters to telehealth companies over compounded GLP-1 marketing in March. In June, it sent 25 more. In between, the agency proposed pulling compounded semaglutide and tirzepatide off the 503B Bulks List entirely — a change that, if finalized, would end most compounded GLP-1 access through telehealth altogether. This is not a slow-moving regulatory story. It is unfolding in real time, and it has direct staffing implications for any telehealth operator running a weight-management or metabolic health line — see our GLP-1 cost-per-visit breakdown for how those programs are typically staffed and priced.

What the FDA is actually flagging

• Marketing claims that imply a compounded product is FDA-approved, FDA-reviewed, or clinically equivalent to an approved drug when it is not.
• Branding that obscures the actual source or manufacturer of the compounded medication behind the telehealth company's own name.
• As of late May, more than 1,700 adverse events tied to compounded semaglutide and tirzepatide — dosing errors and questionable API sourcing among the most cited concerns.

Why this is a staffing problem, not just a legal one

Most of the warning letters target marketing copy, but the underlying exposure sits with clinical oversight. A telehealth platform whose prescribing clinicians aren't reviewing dosing decisions with real clinical judgment — because the intake flow is templated and the visit is asynchronous by design — is the exact model the FDA is scrutinizing. If the 503B exclusion goes through, platforms with thin clinical oversight will have the least room to pivot, because their operating model was built around volume, not individualized clinical review.

The operators in the best position right now are the ones who can show a real prescriber reviewing each case — not just a workflow that routes a form to a signature queue.

What to check before the next warning letter round

• Audit your own marketing language for anything implying FDA approval or equivalence to branded semaglutide or tirzepatide.
• Confirm your clinician-to-patient ratios support actual case review, not just signature throughput.
• Build a contingency plan for a compounded-supply disruption — if the Bulks List exclusion finalizes, patients on compounded product will need a fast transition path to branded product or an alternative protocol.

DirectShifts staffs telehealth GLP-1 programs with licensed physicians and NPs built for real clinical oversight, not template throughput — a conversation worth having before the next enforcement wave, not after. Talk to a clinician partner about what compliant staffing ratios look like for your program.